BioAtla Investor Presentation Deck

Phase 2 CAB-ROR2 (BA3021) in Stage IV Multi-Refractory Melanoma Promising early signals of efficacy - continuing to collect data in ongoing study Completed enrollment Q2W targeted cohort who previously progressed on PD-1/L1 therapy • As of Nov 3, eight melanoma monotherapy patients are evaluable* with reported first scan data across Phase 1 and Phase 2 ● ● ▪ We observed a total of four responses, two stable disease and two progressive disease ▪ Two responses observed in ROR2 TmPS negative patients Phase 2 initial data readout (n = ~20) expected in 1H 2024 bicatla *7 patients in Phase 2 received 1.8 mg/kg Q2W and 1 patient in Phase 1 received 3.0 mg/kg Q3W BioAtla| Overview 46

View entire presentation